Paracetamol (500 mg)/dimethindene maleate (1 mg)/ phenylephrine hydrochloride (10 mg) tablets + Paracetamol (500 mg) tablets
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Upper Respiratory Tract Infection
Conditions
Upper Respiratory Tract Infection, Nasal Congestion, Rhinorrhea, Sneezing
Trial Timeline
Jul 1, 2013 → Aug 1, 2015
NCT ID
NCT01448057About Paracetamol (500 mg)/dimethindene maleate (1 mg)/ phenylephrine hydrochloride (10 mg) tablets + Paracetamol (500 mg) tablets
Paracetamol (500 mg)/dimethindene maleate (1 mg)/ phenylephrine hydrochloride (10 mg) tablets + Paracetamol (500 mg) tablets is a phase 3 stage product being developed by Novartis for Upper Respiratory Tract Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT01448057. Target conditions include Upper Respiratory Tract Infection, Nasal Congestion, Rhinorrhea.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01448057 | Phase 3 | Completed |
Competing Products
20 competing products in Upper Respiratory Tract Infection